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Background: Improved adherence to inhaled corticosteroids (ICS) is recognized as
an important factor in reduced morbidity, mortality and consumption of health care
resources. The present study was designed to replicate pervious reports of patient
adherence with fluticasone/salmeterol in a single inhaler (FSC), fluticasone and
salmeterol in separate inhalers (FP+SAL), fluticasone and montelukast (FP+MON),
fluticasone alone (FP) and montelukast alone (MON).
Methods: A 24-month observational retrospective study was conducted using
administrative claims data. Subjects were X12 years old with 24 months of
continuous enrollment; had X1 asthma claim (ICD-9: 493), X1 short-acting beta2-
agonist claim, and X1 FSC, FP, SAL, or MON claim. Outcomes included asthma
medication refill rates and persistence measured by treatment days. This study was
designed with a unique population of patients with asthma from different health
plans to validate previous findings.
Results: A total of 3503 subjects were identified based on their index medication:
FSC (996), FP+SAL (259), FP+MON (101), FP (1254) and MON (893). Mean number of
prescription refills for FSC (3.98) was significantly higher than FP (2.29) and the FP
component of FP+SAL (2.36), and FP+MON (2.15), Po0:05: No significant differences
were observed between FSC and MON fill rates (4.33). Mean number of treatment
days was greater for FSC compared to FP, FP+SAL, and FP+MON (Po0:0001).
Conclusion: This study confirms a previous report that adherence profiles of
fluticasone and salmeterol in a single inhaler are significantly better when comparedElsevier Ltd. All rights reserved.
(D.A. Stempel).
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fluticasone and montelukast, or fluticasone alone and similar to montelukast alone.
& 2005 Elsevier Ltd. All rights reserved.Introduction
Inhaled corticosteroids (ICS) have been identified
by both the National Asthma Education Prevention
Program and the Global Initiative for Asthma (GINA)
as the preferred component of controller therapy
for patients of all ages and all severity levels of
persistent asthma.1,2 In addition these guidelines
recommend the addition of a long-acting broncho-
dilator for patients whose asthma is not controlled
with an ICS alone. Increased adherence to therapy
with ICS is associated with a reduction in emer-
gency department visits, hospitalizations and mor-
tality.3–6 Studies show that significant reduction in
asthma-related morbidity and mortality are
achieved with modest refill persistence of 4–6
canisters of ICS dispensed per year.5,6
However, low patient adherence with ICS is
common. Refill data indicate that patients treated
with ICS have, on average, only 2–4 units of the
medication dispensed per year.7,8 Poor adherence
to ICS is recognized as a contributor to asthma
treatment failure resulting in increased morbidity,
mortality and increased consumption of health care
resources.9 Furthermore, adherence to pharma-
ceutical agents in clinical practice may be lower
than demonstrated in controlled clinical trials.10
This study was designed to confirm previous
findings that demonstrated increased patient ad-
herence with fluticasone and salmeterol in a single
inhaler when compared to the inhaled corticoster-
oid component of fluticasone and salmeterol in
separate inhalers, fluticasone and montelukast
combination and with fluticasone monotherapy
using administrative claims data.8 This study
employed a unique population of patients with
asthma, in different health plans, different regions
of the country and included Medicaid patients not
previously studied.Methods
Data source and timeframe
An observational retrospective cohort study was
conducted using administrative claims data from
three commercial health plans and one Medicaid
plan. The commercial health plans with 8 million
members and a Medicaid plan that included bothMedicaid-managed care and discounted fee-for-
service covering more than 1.6 million recipients.
The study period included data from April 1, 2000
to September 30, 2002, which allowed for a 24-
month study period (12 months pre-index and 12
months post-index), with the index period occur-
ring between April 1 and September 30, 2001.Cohort definitions
The study participants were divided into the
following five cohorts based on the asthma con-
troller medication(s) filled during the index period:
(1) fluticasone propionate and salmeterol in a
single dry powder inhaler (FSC), (2) fluticasone
propionate and salmeterol in separate inhalers
dispensed within 60 days of each other (FP+SAL),
(3) fluticasone propionate alone (FP), (4) flutica-
sone propionate and montelukast dispensed within
60 days of each other (FP+MON), (5) montelukast
alone (MON). The first identified controller regimen
was defined as the index medication(s). The study
period for each patient started 12 months prior to
the patient’s index medication and continued for
12 months post-index.Study population
Subjects in this analysis were required to have one
principal or secondary medical diagnosis claim for
asthma (International Classification of Diseases,
Ninth Revision [ICD-9]: 493.XX) and at least one
short-acting beta2-agonist (SABA) prescription
claim in the pre-index period. Subjects had one or
more pharmacy claim(s) for the medications of
interest (FSC, FP, SAL, or MON) during the index
period, were 12 years old or older on the index
date, and were continuously enrolled during the
24-month study period. Subjects with chronic
obstructive lung disease (ICD-9: 491.XX, 492.XX,
494.XX, and 496.XX) or cystic fibrosis (ICD-9:
277.0X) claims during the 24-month study period
or claims for any ICS, long-acting beta2-agonist
(LABA), or leukotriene modifier (LTM) prescriptions
during the 12-month pre-index period were ex-
cluded. In order to attain comparable cohorts,
patients using the highest strengths of FSC (500/
50mcg) and FP (220mcg) were excluded from the
analyses. During the 60 days after the index event,
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controller therapy.Outcomes
The outcomes of interest in the post-index period
were (1) asthma medication refill rates and (2)
treatment days used as a measure of persistence.
Asthma medication refill rates were defined as the
number of 1-month (30-day) supply of the medica-
tion of interest during the 12-month post-index
period. Treatment days for the monotherapy (FSC,
FP, and MON) cohorts constituted the total days
supply of the medication in the post-index period.
Treatment days were calculated for the combina-
tion cohorts (FP+SAL and FP+MON) as the total
number of days when the FP component of the
regimen was supplied. The index prescription for
the medication of interest was included in the
analyses of refill rates and treatment days. Pre-
scriptions for a 3-month supply were adjusted for
this method of dispensing. SABA refill rates in the
post-index period were also analyzed for the five
cohorts.Analysis
Descriptive statistics were calculated for each
study cohort. Mean and standard deviation or
percentage were calculated for continuous and
count variables including age, gender, SABA utiliza-
tion, comorbidities, and percent with a pulmonary
function test in the 12-month pre-index period.
Chi-square tests were applied for each categorical
variable (gender and pulmonary function test) and
Wilcoxon rank tests were performed to test the
difference between the cohorts for continuousTable 1 Demographics and subject characteristics.
Characteristics FSC FP+S
n 996 259
Male (%) 353 (35.4%) 86 (
Mean age (SD) 39.5 (17.2)M,Z 41.2
Mean SABA use (SD) 3.00 (3.46)M,F 2.72
Mean no. of comorbidities (SD) 1.39 (1.33)M,F,Z 1.34
Pulmonary function testy 36.9%M,C,F,Z 28.2
MSignificant difference between FSC and MON cohorts Po0:05:
CSignificant difference between FSC and FP+SAL cohorts Po0:05:
FSignificant difference between FS and FP cohorts Po0:05:
ZSignificant difference between FS and FP+MON cohorts Po0:05:
MON ¼ montelukast (5 and 10mg).
yPercent with at least one test.variables (mean age, mean SABA utilization, and
mean number of comorbidities).
ANOVA models were used to assess the differ-
ences in refill rates and treatment days. For the
subjects in the FP+SAL and the FP+MON cohorts,
the amount of FP refills and days supply were
compared. The models were adjusted for baseline
measures, some of which are proxies for severity,
including baseline comorbidities, medication use,
and hospitalization. All analyses controlled for
demographics, health plan, comorbidities, pre-
index medication use, pre-index asthma ED/hospi-
talization, and pre-index asthma-related proce-
dures such as nebulizer, injection of asthma-related
drugs, pulmonary function test, and allergy skin
test. Differences between the cohorts were defined
as statistically significant at Po0:05: SASs Proprie-
tary Software, Release 8.2 was used for all
statistical analyses (SAS Institute Inc., Cary, NC).Results
Subjects
A total of 3503 subjects were identified in the
administrative claims data. On the basis of the
index medication(s) the patients were classified in
one of the following cohorts: FSC (n ¼ 996), FP
(n ¼ 1254), FP+SAL (n ¼ 259), FP+MON (n ¼ 101)
and MON (n ¼ 893). Baseline demographics are
presented in Table 1. Subjects dispensed FSC were
older than those dispensed MON and FP+MON. Mean
pre-index SABA use for FSC cohort was significantly
higher than for the FP subjects and lower than for
MON patients. The FSC cohort had a greater
number of comorbidities than those in the MON,AL FP FP+MON MON
1254 101 893
33.2%) 466 (37.2%) 41 (40.6%) 317 (35.5%)
(16.3) 38.8 (18.0) 34.7 (18.0) 34.8 (18.3)
(3.37) 2.45 (2.89) 3.09 (4.38) 3.10 (3.48)
(1.32) 1.22 (1.42) 1.08 (1.30) 1.16 (1.31)
% 20.7% 22.8% 26.3%
ARTICLE IN PRESS
D.A. Stempel et al.1266FP, and FP+MON cohorts. A significantly higher
percentage of the FSC cohort had claims for
pulmonary function testing pre-index event when
compared to the other groups.
Refill rates
The distribution of the mean number of ICS
medication fills dispensed in the five cohorts in
the post-index period is shown in Fig. 1. The mean
number of medication fills obtained by FSC cohort
(3.98; 95% CI 3.78–4.18) was nearly twice that of FP
cohort (2.29; 95% CI 2.11–2.47), and of the
corticosteroid components of FP+SAL (2.36; 95% CI
1.97–2.75), and FP+MON (2.15; 95% CI 1.52–2.78)
cohorts (Po0:05). There were no significant differ-
ences in the mean number of fills between FSC and
MON (4.33; 95% CI 4.11–4.54).
Treatment days
The mean number of treatment days for FSC
(84.76; 95% CI 79.82–89.69) was statistically great-
er (Po0:0001) than for FP+SAL (26.76; 95% CI
17.11–36.40), FP+MON cohort (25.44; 95% CI
10.03–40.84), and FP (29.24; 95% CI 24.84–33.65).
There were no significant differences (P ¼ 0:10)
between the mean number of treatment days for
FSC and MON (78.10; 95% CI 72.89–83.31).
Post-index SABA use
The mean number of SABA prescriptions in the 12-
month post-index period for FSC cohort (2.34; 95%
CI 2.14–2.55) was significantly lower (Po0:0001)
than the number of SABA prescriptions for MON
cohort (2.79; 95% CI 2.57–3.01). There were no0
1
2
3
4
5
    FSC    
(n=996)
FP+SAL
(n=259)
    FP       
(n=1,254)
FP+MON
(n=101)
MON
(n=893)
 
 
Pr
es
cr
ip
tio
n 
C
la
im
s/p
at
ie
nt
 
*
Figure 1 Mean number of FP prescription claims dis-
pensed in the 12-month post-index period. *Po0:05 for
FSC compared to FP+SAL, FP, FP+MON, P ¼ 0:06 for FSC
compared to MON.significant differences in the mean number of SABA
prescriptions dispensed post-index between FSC
and FP+SAL (2.59; 95% CI 2.18–2.99); FP (2.62; 95%
CI 2.43–2.80); or FP+MON (2.55; 95% CI 1.91–3.20).Discussion
This study demonstrates that FSC provides the
highest level of adherence to the ICS component of
controller therapy and equivalent adherence to
montelukast alone. The annual refill rate for FSC
was 69–85% higher than the rates for FP, as well as
the FP component in FP+SAL, and FP+MON cohorts.
In addition, there was no difference in adherence
between FSC and montelukast monotherapy. This
study in a unique population (different health
plans, different regions of the country and inclusion
of Medicaid claims) confirms a previous report
demonstrating that therapy with fluticasone pro-
pionate and salmeterol in a single inhalation device
is an effective means of achieving adherence to
inhaled corticosteroid therapy for asthma.8 The
consistent findings from the two studies increase
the generalizability of the results.
The study has several limitations. It is an
observational investigation of administrative med-
ical and pharmacy claims data that were collected
for the primary purpose of reimbursement. These
data sets do not include information on the clinical
status of these patients. In addition, the days’
supply of controller medication dispensed is a proxy
for medication adherence and does not record
actual patient adherence behavior with regards to
the medication. There may also be other factors
influencing these results such as samples and
’ ’
borrowed’’ medications not included in this
analysis that may alter adherence measures. These
limitations may overestimate or underestimate the
actual use of the medications, but this bias should
be expected to occur in each of the cohorts
similarly.
Despite advances in therapy, asthma continues to
have significant impact on morbidity, mortality and
consumption of health care resources. Proper
management of asthma and increased adherence
to treatment regimen may result in improved long-
term asthma control. The literature suggests that
simplification of the treatment regimen with fewer
medications should achieve better adherence.11,12
Perceived improvement and simpler medical regi-
mens may motivate and improve patient adher-
ence. This study confirms the findings of a previous
paper8 with claims data of unique patients with
asthma from different regions and different payer
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with the data from clinical trials demonstrating the
superiority of FSC when compared to other con-
trollers adds to the evidence supporting the
recommendations of GINA and the NAEPP for
controller therapy with ICS+LABA.References
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